BE2014C016I2 - - Google Patents

Download PDF

Info

Publication number
BE2014C016I2
BE2014C016I2 BE2014C016C BE2014C016C BE2014C016I2 BE 2014C016 I2 BE2014C016 I2 BE 2014C016I2 BE 2014C016 C BE2014C016 C BE 2014C016C BE 2014C016 C BE2014C016 C BE 2014C016C BE 2014C016 I2 BE2014C016 I2 BE 2014C016I2
Authority
BE
Belgium
Application number
BE2014C016C
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32185709&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2014C016(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of BE2014C016I2 publication Critical patent/BE2014C016I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BE2014C016C 2002-11-15 2014-02-27 BE2014C016I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10253282A DE10253282A1 (de) 2002-11-15 2002-11-15 Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung

Publications (1)

Publication Number Publication Date
BE2014C016I2 true BE2014C016I2 (fr) 2023-03-07

Family

ID=32185709

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2014C016C BE2014C016I2 (fr) 2002-11-15 2014-02-27

Country Status (38)

Country Link
EP (2) EP1562603B3 (fr)
JP (1) JP4317138B2 (fr)
KR (1) KR101092247B1 (fr)
CN (3) CN101817800A (fr)
AR (2) AR041969A1 (fr)
AT (1) ATE430569T1 (fr)
AU (1) AU2003285326B2 (fr)
BE (1) BE2014C016I2 (fr)
BR (1) BRPI0316264B8 (fr)
CA (1) CA2506082C (fr)
CO (1) CO5570670A2 (fr)
CY (2) CY1110500T1 (fr)
DE (2) DE10253282A1 (fr)
DK (1) DK1562603T3 (fr)
EA (1) EA008665B1 (fr)
EC (1) ECSP055774A (fr)
ES (1) ES2326878T7 (fr)
FR (1) FR14C0049I2 (fr)
HR (1) HRP20050432B1 (fr)
HU (1) HUS1400011I1 (fr)
IL (1) IL167900A (fr)
LT (1) LTC1562603I2 (fr)
LU (1) LU92433I2 (fr)
ME (1) ME00354B (fr)
MX (1) MXPA05005081A (fr)
MY (1) MY136034A (fr)
NL (1) NL300650I2 (fr)
NO (2) NO334314B1 (fr)
NZ (1) NZ540661A (fr)
PE (1) PE20040694A1 (fr)
PL (1) PL212238B1 (fr)
PT (1) PT1562603E (fr)
RS (1) RS51607B (fr)
SI (1) SI1562603T1 (fr)
TW (1) TWI343812B (fr)
UA (1) UA81276C2 (fr)
WO (1) WO2004045618A2 (fr)
ZA (1) ZA200502246B (fr)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
DE102004019539A1 (de) * 2004-04-22 2005-11-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittel zur Behandlung von Atemwegserkrankungen
SI1781298T1 (sl) * 2004-04-22 2012-04-30 Boehringer Ingelheim Int Farmacevtske kombinacije, ki vsebujejo benzoksazine, za zdravljenje respiratornih obolenj
WO2005110990A1 (fr) * 2004-05-13 2005-11-24 Boehringer Ingelheim International Gmbh Heterocycles benzocondenses substitues par hydroxy utilises comme beta-agonistes pour le traitement de maladies respiratoires
DE102004024452A1 (de) * 2004-05-14 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosolformulierung für die Inhalation von Betaagonisten
DE102004024453A1 (de) * 2004-05-14 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Bronchodilatoren zur Behandlung von Atemwegserkrankungen
US7220742B2 (en) 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
US20050256115A1 (en) * 2004-05-14 2005-11-17 Boehringer Ingelheim International Gmbh Aerosol formulation for the inhalation of beta-agonists
US7745621B2 (en) 2004-05-14 2010-06-29 Boehringer Ingelheim International Gmbh Long acting bronchodilators for the treatment of respiratory diseases
DE102004024451A1 (de) * 2004-05-14 2005-12-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverformulierungen für die Inhalation, die Enantiomerenreine Betaagonisten enthalten
DE102004024454A1 (de) * 2004-05-14 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Enantiomerenreine Betaagonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
DE102004045648A1 (de) * 2004-09-21 2006-03-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Betamimetika zur Behandlung von Atemwegserkrankungen
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
DE102005007654A1 (de) 2005-02-19 2006-08-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Betamimetika zur Behandlung von Atemwegserkrankungen
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
DE102005030733A1 (de) * 2005-07-01 2007-01-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen enthaltend langwirksame Beta-2-Agonisten und wenigstens einen weiteren Wirkstoff
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
US7994211B2 (en) 2005-08-08 2011-08-09 Argenta Discovery Limited Bicyclo[2.2.1]hept-7-ylamine derivatives and their uses
MX2008001976A (es) 2005-08-15 2008-03-25 Boehringer Ingelheim Int Procedimiento para la preparacion de betamimeticos.
TWI396541B (zh) * 2005-10-10 2013-05-21 Boehringer Ingelheim Int 用於治療呼吸疾病之新穎藥物組合
TWI389692B (zh) * 2005-10-10 2013-03-21 Boehringer Ingelheim Int 用以吸入β-共效劑的氣溶膠調配物
US7910708B2 (en) 2005-10-21 2011-03-22 Novartis Ag Anti-IL13 human antibodies
CN101296700A (zh) * 2005-11-09 2008-10-29 贝林格尔·英格海姆国际有限公司 吸入用气雾剂制剂
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
CA2642239A1 (fr) * 2006-02-16 2007-08-23 Boehringer Ingelheim International Gmbh Combinaisons medicamenteuses pour le traitement de pathologies des voies respiratoires
PE20080142A1 (es) * 2006-03-15 2008-04-14 Boehringer Ingelheim Int Beta-agonistas enantiomericamente puros y sus procedimientos de preparacion
KR20080110925A (ko) 2006-04-21 2008-12-19 노파르티스 아게 아데노신 ａ２ａ 수용체 효능제로서 사용하기 위한 퓨린 유도체
WO2008017638A1 (fr) * 2006-08-07 2008-02-14 Boehringer Ingelheim International Gmbh Nouveaux agonistes beta énantiomériquement purs, procédés pour leur préparation et leur utilisation comme médicament
UY30542A1 (es) * 2006-08-18 2008-03-31 Boehringer Ingelheim Int Formulacion de aerosol para la inhalacion de agonistas beta
UY30543A1 (es) * 2006-08-18 2008-03-31 Boehringer Ingelheim Int Formulacion de aerosol para la inhalacion de beta- agonistas
DE602007013441D1 (de) 2006-09-29 2011-05-05 Novartis Ag Pyrazolopyrimidine als pi3k-lipidkinasehemmer
CA2667962A1 (fr) 2006-10-30 2008-05-08 Novartis Ag Composes heterocycliques en tant qu'agents anti-inflammatoires
DE602007011670D1 (de) 2007-01-10 2011-02-10 Irm Llc Verbindungen und zusammensetzungen als kanal-aktivierende proteasehemmer
MX2009005813A (es) * 2007-01-25 2009-06-16 Boehringer Ingelheim Int Procedimiento para la preparacion de betamimeticos.
BRPI0811562A2 (pt) 2007-05-07 2014-12-09 Novartis Ag Compostos orgânicos
EP2231280B1 (fr) 2007-12-10 2016-08-10 Novartis AG Pyrazine carboxamides semblable à l'Amiloride en tant que bloqueurs d'ENaC
PL2231642T3 (pl) 2008-01-11 2014-04-30 Novartis Ag Pirymidyny jako inhibitory kinazy
US8236808B2 (en) 2008-06-10 2012-08-07 Novartis Ag Pyrazine derivatives as ENAC blockers
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
NZ594157A (en) 2008-12-30 2013-07-26 Pulmagen Therapeutics Inflammation Ltd Sulfonamide compounds for the treatment of respiratory disorders
PT2391366E (pt) 2009-01-29 2013-02-05 Novartis Ag Benzimidazoles substituídos para o tratamento de astrocitomas
WO2010150014A1 (fr) 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited Glitazones 5r-5–deutérés pour le traitement de maladies respiratoires
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
EP2464649A1 (fr) 2009-08-12 2012-06-20 Novartis AG Composés hydrazone hétérocycliques et leurs utilisations pour traiter le cancer et l'inflammation
NZ598220A (en) 2009-08-17 2014-02-28 Intellikine Llc Heterocyclic compounds and uses thereof
CA2777245A1 (fr) 2009-10-22 2011-04-28 Vertex Pharmaceuticals Incorporated Compositions destinees au traitement de la mucoviscidose et d'autres maladies chroniques
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
WO2011098746A1 (fr) 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Sels d'addition acide cristallins de l'énantiomère (5r) de la pioglitazone
GB201002243D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
GB201002224D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
WO2012034095A1 (fr) 2010-09-09 2012-03-15 Irm Llc Composés et compositions comme inhibiteurs de trk
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
BR112013007469B1 (pt) * 2010-09-21 2020-03-31 Intekrin Therapeutics, Inc. Composições farmacêuticas antidiabéticas sólidas, seu uso e método de preparação, método para preparar um produto de granulação e composição precursora farmacêutica
JP2014505088A (ja) 2011-02-10 2014-02-27 ノバルティス アーゲー Ｃ−ＭＥＴチロシンキナーゼ阻害剤としての［１，２，４］トリアゾロ［４，３−ｂ］ピリダジン化合物
JP5808826B2 (ja) 2011-02-23 2015-11-10 インテリカイン， エルエルシー 複素環化合物およびその使用
US9102671B2 (en) 2011-02-25 2015-08-11 Novartis Ag Compounds and compositions as TRK inhibitors
UY34305A (es) 2011-09-01 2013-04-30 Novartis Ag Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
UY34329A (es) 2011-09-15 2013-04-30 Novartis Ag Compuestos de triazolopiridina
ES2558457T3 (es) 2011-09-16 2016-02-04 Novartis Ag Compuestos heterocíclicos para el tratamiento de fibrosis quística
WO2013038381A1 (fr) 2011-09-16 2013-03-21 Novartis Ag Dérivés d'amide pyridine/pyrazine
WO2013038378A1 (fr) 2011-09-16 2013-03-21 Novartis Ag Dérivés pyridinamides
WO2013038373A1 (fr) 2011-09-16 2013-03-21 Novartis Ag Dérivés pyrimidinamides
EP2755652B1 (fr) 2011-09-16 2021-06-02 Novartis AG Hétérocyclyle carboxamides n-substitués
US9174994B2 (en) 2011-11-23 2015-11-03 Intellikine, Llc Enhanced treatment regimens using mTor inhibitors
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
CN104245701A (zh) 2012-04-03 2014-12-24 诺华有限公司 有酪氨酸激酶抑制剂的组合产品和其应用
EP2906218B1 (fr) 2012-10-09 2016-12-14 Boehringer Ingelheim International GmbH Agoniste des récepteurs 2-adrénergiques utilisé dans le traitement de la toux
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
EP2968340A4 (fr) 2013-03-15 2016-08-10 Intellikine Llc Combinaison d'inhibiteurs de kinase et ses utilisations
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
BR112016023967A2 (pt) 2014-04-24 2017-08-15 Novartis Ag derivados de pirazina como inibidores de fosfatidilinositol 3-cinase
JP6433509B2 (ja) 2014-04-24 2018-12-05 ノバルティス アーゲー ホスファチジルイノシトール３−キナーゼ阻害薬としてのアミノピラジン誘導体
WO2015162456A1 (fr) 2014-04-24 2015-10-29 Novartis Ag Dérivés aminés de pyridine utilisables en tant qu'inhibiteurs de la phosphatidylinositol 3-kinase
WO2016011658A1 (fr) 2014-07-25 2016-01-28 Novartis Ag Polythérapie
KR20170036037A (ko) 2014-07-31 2017-03-31 노파르티스 아게 조합 요법
JP2019536812A (ja) 2016-12-12 2019-12-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング オロダテロールとの同時投与による間質性肺疾患の処置方法に使用するためのニンテダニブ
PL3558954T3 (pl) 2016-12-20 2022-01-31 Inke, S.A. Ulepszony sposób wytwarzania chlorowodorku r-6-hydroxy-8-[1-hydroksy-2-[2-(4-metoksyfenylo)-1,1-dimetyloetyloaminoetylo]-2h-1,4-benzoksazyno-3(4h)-onu
CN108997248B (zh) * 2018-08-06 2023-08-01 上海方予健康医药科技有限公司 盐酸奥达特罗晶型b及其制备方法
CN109096218B (zh) * 2018-08-06 2020-10-27 上海方予健康医药科技有限公司 盐酸奥达特罗晶型a及其制备方法
US20200383960A1 (en) 2019-06-10 2020-12-10 Novartis Ag Pyridine and Pyrazine derivative for the Treatment of CF, COPD, and Bronchiectasis
JP2022547427A (ja) 2019-08-28 2022-11-14 ノバルティス アーゲー 置換１，３－フェニルヘテロアリール誘導体及び疾患の治療におけるその使用
US11304897B2 (en) 2020-06-09 2022-04-19 Anovent Pharmaceutical (U.S.), Llc Pharmaceutical formulation containing umeclidinium bromide and vilanterol trifenatate
US11331322B1 (en) 2021-09-15 2022-05-17 Santen Pharmaceutical Co., Ltd. Medicament for preventing and/or treating dry eye

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3134590A1 (de) 1981-09-01 1983-03-10 Boehringer Ingelheim KG, 6507 Ingelheim Neue benzo-heterocyclen
US4460581A (en) 1982-10-12 1984-07-17 Boehringer Ingelheim Kg (1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones
DE3743265A1 (de) * 1987-12-19 1989-06-29 Boehringer Ingelheim Kg Neue ammoniumverbindungen, ihre herstellung und verwendung
IL152140A0 (en) * 2000-04-27 2003-05-29 Boehringer Ingelheim Pharma Novel, slow-acting betamimetics, a method for their production and their use as medicaments

Also Published As

Publication number Publication date
CA2506082A1 (fr) 2004-06-03
EP1562603B1 (fr) 2009-05-06
CN101817800A (zh) 2010-09-01
ES2326878T7 (es) 2014-03-11
FR14C0049I1 (fr) 2014-08-08
JP2006508140A (ja) 2006-03-09
WO2004045618A3 (fr) 2004-09-30
CN101735166A (zh) 2010-06-16
AR041969A1 (es) 2005-06-01
CY2014032I2 (el) 2015-12-09
BRPI0316264B8 (pt) 2021-05-25
AU2003285326B2 (en) 2009-06-04
PL375270A1 (en) 2005-11-28
CO5570670A2 (es) 2005-10-31
NO2014005I1 (no) 2014-03-10
HRP20050432B1 (en) 2012-01-31
TWI343812B (en) 2011-06-21
LU92433I2 (fr) 2014-06-24
EA008665B1 (ru) 2007-06-29
IL167900A (en) 2013-06-27
ZA200502246B (en) 2006-01-25
CN1713914A (zh) 2005-12-28
CY2014032I1 (el) 2015-12-09
EP1562603A2 (fr) 2005-08-17
ES2326878T3 (es) 2009-10-21
WO2004045618A2 (fr) 2004-06-03
MEP53608A (en) 2011-05-10
BRPI0316264B1 (pt) 2019-04-09
JP4317138B2 (ja) 2009-08-19
HUS1400011I1 (hu) 2022-02-28
PE20040694A1 (es) 2004-11-23
NL300650I2 (nl) 2017-11-02
MY136034A (en) 2008-07-31
DE50311502D1 (de) 2009-06-18
PL212238B1 (pl) 2012-08-31
UA81276C2 (en) 2007-12-25
CA2506082C (fr) 2011-06-21
DK1562603T3 (da) 2009-09-07
BR0316264A (pt) 2005-10-11
CY1110500T1 (el) 2015-04-29
ECSP055774A (es) 2005-11-22
TW200423943A (en) 2004-11-16
NO20052883L (no) 2005-06-14
EP2025338A1 (fr) 2009-02-18
MXPA05005081A (es) 2005-07-01
RS20050361A (en) 2007-04-10
LTC1562603I2 (lt) 2016-12-12
KR101092247B1 (ko) 2011-12-12
AR087241A2 (es) 2014-03-12
FR14C0049I2 (fr) 2015-07-24
EA200500715A1 (ru) 2005-12-29
AU2003285326A1 (en) 2004-06-15
RS51607B (sr) 2011-08-31
KR20050075013A (ko) 2005-07-19
PT1562603E (pt) 2009-06-18
HRP20050432A2 (en) 2006-06-30
NZ540661A (en) 2007-12-21
ME00354B (fr) 2011-10-10
SI1562603T1 (sl) 2009-10-31
EP1562603B3 (fr) 2014-01-08
NO334314B1 (no) 2014-02-03
DE10253282A1 (de) 2004-05-27
ATE430569T1 (de) 2009-05-15

Similar Documents

Publication Publication Date Title
BE2019C547I2 (fr)
BE2019C510I2 (fr)
BE2018C021I2 (fr)
BE2017C049I2 (fr)
BE2017C005I2 (fr)
BE2016C069I2 (fr)
BE2016C040I2 (fr)
BE2016C013I2 (fr)
BE2018C018I2 (fr)
BE2016C002I2 (fr)
BE2015C078I2 (fr)
BE2015C017I2 (fr)
BE2014C053I2 (fr)
BE2014C051I2 (fr)
BE2014C041I2 (fr)
FR14C0049I1 (fr)
BE2014C030I2 (fr)
BE2014C015I2 (fr)
BE2013C063I2 (fr)
BE2013C039I2 (fr)
BE2015C069I2 (fr)
BE2011C038I2 (fr)
JP2003122509A5 (fr)
JP2003116134A5 (fr)
BRPI0215435A2 (fr)